Center For Cough Clinical Research

Investigating New Cough Drugs

Dr. Mandel Sher is a leading investigator of new cough medications.  Dr. Sher advises national and global scientists and researchers developing new cough drugs.  

Center for Cough conducts clinical research studies as part of the process of FDA approval for new chronic cough treatment options. These studies are sponsored by pharmaceutical companies and give patients who qualify, and volunteer to participate in these studies, access to the most current treatment options before they become available to the general public.

Adults who have a cough for 1 year or longer are invited to contact Center for Cough’s Clinical Research Nurse Coordinator, Carol, directly at 727-210-3259 to learn about current research trials.  Patient participation in research studies is always voluntary. Volunteers are carefully selected based on meeting specific criteria. Patients do not need to have health insurance to participate. Study medications, labs, examinations, and other medical tests are provided at no cost to eligible patients. Tampa Bay area’s Center for Cough has been conducting national and global pharmaceutical trials since 2009.

Center for Cough’s full-time Clinical Research Nurse Coordinator,  Carol, is the primary contact for research volunteers.  Carol is a Registered Nurse who earned the prestigious certification of CPN beyond RN licensure.  Carol has many years of experience in patient care, most helping patients with respiratory disorders. Center for Cough appreciates the contribution to chronic cough treatment being made by research study volunteers.

Carol, R.N. CPN | Center For Cough Clinical Research Coordinator

Carol is Center for Cough’s Clinical Research Coordinator.  Carol is a Registered Nurse who also achieved the prestigious certification of CPN beyond RN licensure.  Carol has many years of patient care experience, many of those years dedicated to patients with respiratory conditions  such as chronic cough, allergy, asthma, and immunologic conditions.

Current Studies

Dr. Mandel Sher and Center for Cough are actively enrolling participants in open Cough studies.

If you or someone you know may be interested in joining a Cough study, please contact  Carol, Center for Cough’s Clinical Research Nurse Coordinator at 727-210-3259.


Major Breakthrough in Cough Treatment on the Horizon

There’s a major breakthrough in cough treatment on the horizon and it shows promising preliminary results! Dr. Mandel Sher and Center for Cough are currently enrolling volunteer patients in the clinical trials of AF-219, a new drug that shows promise as a breakthrough in cough treatment. For a limited time, patients have an opportunity to […]


Dr. Sher Leads National Conversation on Chronic Cough

“Cough is the most frequent illness-related reason people visit their doctor,” according to the Centers for Disease Control and Prevention’s National Center for Health Statistics. But not all coughs are created equal.   Some people are dealing with an active upper respiratory infection or the aftermath, and others have a cough that just won’t go away.  […]


Clinical Trials Conducted at Center for Cough

Dr. Mandel Sher and Center for Cough are grateful to their many patients who volunteer for clinical trials. The Wall Street Journal reported on April 12, 2016  that fewer than 10% of Americans participate in clinical trials to test new drugs and treatments because they are unaware of that option or their doctors may not […]

AF-219: Promising New Cough Treatment

Dr. Mandel Sher and Center for Cough are the nation’s leading site for clinical research trials for new cough treatments.  Currently, Center for Cough is enrolling eligible patients in Afferent Pharmaceuticals AF-219 clinical research trial. Preliminary results suggest AF-219 may be a promising new cough treatment. Contact Amy, Center for Cough’s Clinical Research Coordinator, to […]


Positive Results in Chronic Cough Trial

Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial AF-219 Treatment Significantly Reduces Cough Frequency in Patients SAN MATEO, Calif.–(BUSINESS WIRE)–Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting P2X3 for the treatment of poorly managed and common neurogenic disorders, such as chronic cough, today announced positive top-line results from […]